Orexigen® Therapeutics Schedules November 3, 2010 Webcast Discussion of Financial Results for the Third Quarter Ended September

SAN DIEGO, Oct. 28 /PRNewswire-FirstCall/ -- Orexigen® Therapeutics, Inc. (Nasdaq: OREX), a biopharmaceutical company focused on the treatment of obesity, will announce financial results for the third quarter ended September 30,2010 on Wednesday, November 3, 2010 after the markets close. The announcement will be followed by a live webcast and conference call at 5:00 p.m. Eastern time.

Orexigen management will host the call and webcast to discuss financial results and recent business highlights. The live call may be accessed by phone by calling (800) 884-5695 (domestic) or (617) 786-2960 (international), participant code 70229939. The webcast can be accessed live on the investor relations section of the Orexigen web site at www.orexigen.com and will be archived for 14 days following the call.

About Orexigen Therapeutics

Orexigen Therapeutics, Inc. is a biopharmaceutical company focused on the treatment of obesity. The Company has filed an NDA with the FDA for its lead investigational product, Contrave®. The U.S. Food and Drug Administration (FDA) has scheduled the Endocrinologic and Metabolic Drugs Advisory Committee meeting on December 7, 2010 and the Prescription Drug User Fee Act (PDUFA) action date has been set for January 31, 2011. The Company's second product, Empatic™, has completed Phase 2 clinical development. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss, through combination therapeutic approaches. Further information about the Company can be found at www.orexigen.com.

SOURCE Orexigen Therapeutics, Inc.

Suggested Articles

Halozyme CEO Helen Torley discusses how the company stayed alive after its lead program, a treatment for pancreatic cancer, failed in phase 3.

The under-active genes that cause heart problems and poor muscle movement in Down syndrome may also impede the growth of solid tumors, a study found.

The new funding will bankroll Dyne's preclinical programs in three muscle-wasting diseases, as well as discovery-stage work.